Corrrect!
4. All of the above

Patients with anti-MDA-5 ILD progress very quickly and may be refractory to conventional treatment such as corticosteroids. Experience is limited, but typically, a combination of immunosuppressive therapies is necessary (6). Because of this mortality with this condition remains very high.

References

  1. Mueller-Mang C, Grosse C, Schmid K, Stiebellehner L, Bankier AA. What every radiologist should know about idiopathic interstitial pneumonias. Radiographics. 2007 May-Jun;27(3):595-615. [CrossRef] [PubMed]
  2. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824. [CrossRef] [PubMed]
  3. Lynch DA, Newell JD, Logan PM, King TE Jr, Müller NL. Can CT distinguish hypersensitivity pneumonitis from idiopathic pulmonary fibrosis? AJR Am J Roentgenol. 1995 Oct;165(4):807-11. [CrossRef] [PubMed]
  4. Morganroth PA, Kreider ME, Okawa J, Taylor L, Werth VP. Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendations. Arch Dermatol. 2010 Jul;146(7):729-38. [CrossRef] [PubMed]
  5. Hozumi H, Fujisawa T, Nakashima R, Johkoh T, Sumikawa H, Murakami A, Enomoto N, Inui N, Nakamura Y, Hosono Y, Imura Y, Mimori T, Suda T. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease. Respir Med. 2016 Dec;121:91-99. [CrossRef] [PubMed]
  6. Mehta P, Machado PM, Gupta L. Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry. Rheumatol Int. 2021 Jun;41(6):1021-1036. [CrossRef] [PubMed]

Home/Critical Care